4/25
10:38 am
espr
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar [Yahoo! Finance]
Low
Report
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar [Yahoo! Finance]
4/23
08:12 am
espr
Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]
Medium
Report
Esperion to Report First Quarter 2024 Financial Results on May 7 [Yahoo! Finance]
4/23
08:00 am
espr
Esperion to Report First Quarter 2024 Financial Results on May 7
Medium
Report
Esperion to Report First Quarter 2024 Financial Results on May 7
4/10
08:05 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
4/7
02:49 pm
espr
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity [Yahoo! Finance]
Medium
Report
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity [Yahoo! Finance]
4/7
02:45 pm
espr
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Medium
Report
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
4/1
08:19 am
espr
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 [Yahoo! Finance]
Medium
Report
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 [Yahoo! Finance]
4/1
08:00 am
espr
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Low
Report
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
3/28
01:39 pm
espr
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? [Yahoo! Finance]
3/26
08:00 am
espr
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
3/25
04:06 pm
espr
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 [Yahoo! Finance]
Medium
Report
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 [Yahoo! Finance]
3/25
04:00 pm
espr
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Medium
Report
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
3/25
01:00 pm
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/25
08:06 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
3/22
06:26 pm
espr
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Low
Report
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
3/22
03:19 pm
espr
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use [Yahoo! Finance]
Medium
Report
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use [Yahoo! Finance]
3/22
03:10 pm
espr
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Medium
Report
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
3/22
11:14 am
espr
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events [Yahoo! Finance]
Medium
Report
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events [Yahoo! Finance]
3/22
11:04 am
espr
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Medium
Report
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
2/29
10:45 am
espr
5 Small Drug Stocks to Buy From a Rebounding Industry [Yahoo! Finance]
Medium
Report
5 Small Drug Stocks to Buy From a Rebounding Industry [Yahoo! Finance]
2/28
02:29 pm
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at HC Wainwright from $22.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at HC Wainwright from $22.00 to $16.00. They now have a "buy" rating on the stock.
2/28
08:46 am
espr
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/27
04:10 pm
espr
4 Tips to Get High Cholesterol Under Control [Yahoo! Finance]
High
Report
4 Tips to Get High Cholesterol Under Control [Yahoo! Finance]
2/27
03:12 pm
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
2/27
08:04 am
espr
Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 [Yahoo! Finance]
High
Report
Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 [Yahoo! Finance]